Home
CMND
CMND News

Latest Clearmind Medicine Inc. (CMND) News on June 8, 2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

GlobeNewswire

3 days ago

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

GlobeNewswire

18 days ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

GlobeNewswire

a month ago

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks

a month ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

GlobeNewswire

a month ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

GlobeNewswire

a month ago

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

GlobeNewswire

2 months ago

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

GlobeNewswire

2 months ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

GlobeNewswire

2 months ago

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

GlobeNewswire

2 months ago

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

TipRanks

2 months ago

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

GlobeNewswire

2 months ago

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

GlobeNewswire

2 months ago

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

GlobeNewswire

2 months ago

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks

3 months ago

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

TipRanks

3 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

GlobeNewswire

3 months ago

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

GlobeNewswire

3 months ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

GlobeNewswire

3 months ago

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks

3 months ago

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire

3 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire

3 months ago

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Psychedelic: GH Research, Compass Pathways report earnings results

TipRanks

3 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

GlobeNewswire

4 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

GlobeNewswire

4 months ago

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Clearmind Medicine Announces Shareholders Meeting Results

GlobeNewswire

5 months ago

Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

GlobeNewswire

5 months ago

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

GlobeNewswire

5 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

GlobeNewswire

5 months ago

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Clearmind Medicine to move forward with MEAI-based alcohol substitute

TipRanks

5 months ago

Clearmind Medicine to move forward with MEAI-based alcohol substitute

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

GlobeNewswire

5 months ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

GlobeNewswire

5 months ago

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

GlobeNewswire

6 months ago

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

GlobeNewswire

8 months ago

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

GlobeNewswire

9 months ago

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

GlobeNewswire

9 months ago

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire

9 months ago

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire

9 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

GlobeNewswire

9 months ago

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

Market Exclusive

9 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

GlobeNewswire

10 months ago

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

GlobeNewswire

10 months ago

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

GlobeNewswire

10 months ago

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

GlobeNewswire

10 months ago

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

GlobeNewswire

10 months ago

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

GlobeNewswire

a year ago

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

GlobeNewswire

a year ago

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

GlobeNewswire

a year ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

GlobeNewswire

a year ago

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

GlobeNewswire

a year ago

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

GlobeNewswire

a year ago

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

GlobeNewswire

a year ago

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

GlobeNewswire

a year ago

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

GlobeNewswire

a year ago

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

GlobeNewswire

a year ago

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Clearmind Applies to Cease Being a Reporting Issuer in Canada

GlobeNewswire

a year ago

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

GlobeNewswire

a year ago

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

GlobeNewswire

a year ago

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine CEO Issues Letter to Shareholders

GlobeNewswire

a year ago

Clearmind Medicine CEO Issues Letter to Shareholders

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

GlobeNewswire

a year ago

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

GlobeNewswire

a year ago

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

GlobeNewswire

a year ago

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

GlobeNewswire

a year ago

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

GlobeNewswire

a year ago

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

GlobeNewswire

a year ago

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

News Direct

a year ago

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire

a year ago

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

GlobeNewswire

a year ago

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

GlobeNewswire

a year ago

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

GlobeNewswire

a year ago

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

GlobeNewswire

a year ago

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

University Expands Emergency Communication Conversion with Knightscope

Business Wire

a year ago

University Expands Emergency Communication Conversion with Knightscope

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

a year ago

Envoy Medical, Inc. to Present at The Microcap Conference

Fortune 500 Client Renews Knightscope Agreement for 3rd Year

Business Wire

a year ago

Fortune 500 Client Renews Knightscope Agreement for 3rd Year

ISG to Publish Reports on Google Cloud Ecosystem

Business Wire

a year ago

ISG to Publish Reports on Google Cloud Ecosystem

SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE

GlobeNewswire

a year ago

SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

GlobeNewswire

a year ago

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Air T, Inc. Announces Dividend Dates for Air T Funding Alpha Income Preferred Securities (AIRTP)

ACCESSWIRE

a year ago

Air T, Inc. Announces Dividend Dates for Air T Funding Alpha Income Preferred Securities (AIRTP)

MCRA Provides Anzu Special Acquisition Corp I with Strategic Diligence Support Leading to Envoy Medical Merger (NASDAQ: COCH)

PR Newswire

a year ago

MCRA Provides Anzu Special Acquisition Corp I with Strategic Diligence Support Leading to Envoy Medical Merger (NASDAQ: COCH)

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

GlobeNewswire

a year ago

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

ACCESSWIRE

a year ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

GlobeNewswire

a year ago

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

ReWalk Robotics Expands Direct Sales Coverage to Canada

GlobeNewswire

a year ago

ReWalk Robotics Expands Direct Sales Coverage to Canada

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

GlobeNewswire

a year ago

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

Clearmind Medicine Completed Type A Meeting with the FDA

GlobeNewswire

a year ago

Clearmind Medicine Completed Type A Meeting with the FDA

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

GlobeNewswire

a year ago

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

GlobeNewswire

a year ago

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

GlobeNewswire

a year ago

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Business Wire

a year ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Lottery.com Inc. Announces $18 Million Commitment from Prosperity Investment Management

GlobeNewswire

a year ago

Lottery.com Inc. Announces $18 Million Commitment from Prosperity Investment Management

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

GlobeNewswire

a year ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Optimistic Investors Push Koss Corporation (NASDAQ:KOSS) Shares Up 32% But Growth Is Lacking

Simply Wall St.

a year ago

Optimistic Investors Push Koss Corporation (NASDAQ:KOSS) Shares Up 32% But Growth Is Lacking

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

GlobeNewswire

a year ago

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Lee Enterprises Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

a year ago

Lee Enterprises Full Year 2023 Earnings: Misses Expectations

Is CBL International Limited's (NASDAQ:BANL) 15% ROE Worse Than Average?

Simply Wall St.

2 years ago

Is CBL International Limited's (NASDAQ:BANL) 15% ROE Worse Than Average?

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

Zacks

2 years ago

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

The Real Brokerage Makes a Big Push Into Kansas City With the Addition of Four Top Producing Teams

Business Wire

2 years ago

The Real Brokerage Makes a Big Push Into Kansas City With the Addition of Four Top Producing Teams

Share on Social Networks: